Gabriel Vargas

Dr. Vargas joined CuraSen in October 2018, bringing more than 12 years of pharmaceutical research and development experience, focused on translational medicine, early clinical development and neuroscience. At Amgen, he most recently held the position of executive medical director, digital health and neuroscience therapeutic area head for early development, and was responsible for the neuroscience portfolio strategy from preclinical research through early development. In this capacity, he led the early development of the recently FDA-approved migraine prophylactic, Aimovig™. Previously, he served as biomarker expert, translational medicine leader and director of discovery medicine at Hoffmann-La Roche (Basel) and Roche Pharmaceuticals (Palo Alto).

Dr. Vargas is a diplomate of the American Board of Psychiatry and Neurology, and currently serves as a volunteer associate clinical professor in psychiatry at the University of California, San Francisco (UCSF).

Dr. Vargas received his MD and PhD in biochemistry from the University of California, Irvine, and completed his residency and fellowship in psychiatry at the University of California, San Francisco.